|
- 2017
载pVAX1/Tat PTD-endostatin壳聚糖纳米基因载体的构建与体外活性评价
|
Abstract:
[1] | 张艳, 马春红,孙汶生, 等. 高生物安全性人内皮抑素载体抑瘤作用的研究[J]. 中国现代普通外科进展, 2004, 7(6): 350-355. ZHANG Yan, MA Chunhong, SUN Wensheng, et al. The antitumor effect of the high bio-safety vector containing human endosatin[J]. Chin J Curr Adv Gen Surg, 2004, 7(6): 350-355. |
[2] | OReilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285. |
[3] | 王晓燕, 袁中芳, 魏增涛, 等. 重组IFN-l蛋白联合endostatin基因对碱烧伤诱导角膜新生血管的抑制作用[J]. 基础医学与临床, 2005, 25(12): 1119-1123. WANG Xiaoyan, YUAN Zhongfang, WEI Zengtao, et al. Inhibitory effect of recombinant IFN-α combined with endostatin gene on corneal neovascurization induced by alkaili burn[J]. Basic and Clinical Medicine, 2005, 25(12): 1119-1123. |
[4] | Mohajeri A, Pilehvar-Soltanahmadi Y, Pourhassan-Moghaddam M, et al. Cloning and expression of recombinant human endostatin in periplasm of Escherichia coli expression system[J]. Adv Pharm Bull, 2016, 6(2): 187-194. |
[5] | Tan H, Yang S, Feng Y, et al. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin[J]. J Biochem, 2008, 144(2): 207-213. |
[6] | 张新科. 穿膜肽Tat PTD介导的内皮抑素穿透眼球屏障及对眼部血管增生抑制作用的研究[D]. 济南:山东大学,2012. ZHANG Xinke. Study on the penetration of eye barrier and inhibition of ocular angiogenesis of endostatin with the mediation of Tat PTD[D]. Jinan: Shandong University, 2012. |
[7] | Ojea-Jiménez I, Tort O,Lorenzo J, et al. Engineered nonviral nanocarriers for intracellular gene delivery applications[J]. Biomed Mater, 2012, 7(5): 054106. doi:10.1088/1748-6041/7/5/054106. |
[8] | Veilleux D, Nelea M, Biniecki K, et al. Preparation of concentrated chitosan/DNA nanoparticle formulations by lyophilization for gene delivery at clinically relevant dosages[J]. J Pharm Sci, 2016, 105(1): 88-96. |
[9] | 姚金凤, 郭晨阳,杨红,等. 壳聚糖纳米粒在药物输送中的应用研究进展[J]. 国际药学研究杂志, 2013, 40(1): 90-94. YAO Jinfeng, GUO Chenyang, YANG Hong, et al. Application of chitosan nanoparicles for drug delivery: research advances[J]. J Int Pharm Res, 2013, 40(1): 90-94. |
[10] | Xing P, Zhang J, Yan Z, et al. Recombined humanized endostatin(Endostar)combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV[J]. Oncotarget, 2017, 8(22): 36716-36727. |
[11] | Wigler M, Silverstein S, Lee LS, et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells[J]. Cell, 1977, 11(1): 223-232. |
[12] | Fu W, Zhuo J, and Hu L. Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer[J]. Oncol Lett, 2017, 13(1): 196-200. |
[13] | Zhang X, Li Y, Cheng Y, et al. Tat PTD-endostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops[J]. Biochim Biophys Acta, 2015, 1850(6): 1140-1149. |
[14] | Li Y, Li L, Li Z, et al. Tat PTD-Endostatin-RGD: a novel protein with anti-angiogenesis effect in retina via eye drops[J]. Biochim Biophys Acta, 2016, 1860(10): 2137-2147. |
[15] | Campochiaro PA, Lauer AK, Sohn EH, et al. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration(GEM)study[J]. Hum Gene Ther, 2017, 28(1): 99-111. |
[16] | Zhang X, Yang X, Ji J, et al. Tumor targeting strategies for chitosan-based nanoparticles[J]. Colloids Surf B Biointerfaces, 2016, 148(1): 460-473. |
[17] | Jung SP, Siegrist B, Hornick CA, et al. Effect of human recombinant endostatin protein on human angiogenesis[J]. Angiogenesis, 2002, 5(1-2): 111-118. |
[18] | Chen J, Liu DG, Yang G, et al. Endostar, a novel human recombinant endostatin, attenuates liver fibrosis in CCl4-induced mice[J]. Exp Biol Med, 2014, 239(8): 998-1006. |
[19] | Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells[J]. Biochem Biophys Res Commun, 2007, 361(1): 79-84. |
[20] | Rezaee M, Oskuee RK, Nassirli H, et al. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems[J]. J Control Release, 2016, 236(1): 1-14. |
[21] | Jain AK, Massey A, Yusuf H, et al. Development of polymeric-cationic peptide composite nanoparticles, a nanoparticle-in-nanoparticle system for controlled gene delivery[J]. Int J Nanomedicine, 2015, 10(1): 7183-7196. |
[22] | Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers[J]. Int J Nanomedicine, 2011,(6): 765-774. |
[23] | Ramesan RM, Sharma CP. Modification of chitosan nanoparticles for improved gene delivery[J]. Nanomedicine, 2012, 7(1): 5-8. |
[24] | Babu A, Ramesh R. Multifaceted applications of chitosan in cancer drug delivery and therapy[J]. Mar Drugs, 2017, 15(4): 96-104. |
[25] | Key J, Park K. Multicomponent, tumor-homing chitosan nanoparticles for cancer imaging and therapy[J]. Int J Mol Sci, 2017, 18(3): 594-612. |
[26] | Petkar KC, Chavhan SS, Agatonovik-Kustrin S, et al. Nanostructured materials in drug and gene delivery: a review of the state of the art[J]. Crit Rev Ther Drug Carrier Syst, 2011, 28(2): 101-164. |